Novel Drug Delivery Systems Tailored for Improved Administration of Glucocorticoids

Glucocorticoids (GC) are one of the most popular and versatile classes of drugs available to treat chronic inflammation and cancer, but side effects and resistance constrain their use. To overcome these hurdles, which are often related to the uniform tissue distribution of free GC and their short ha...

Full description

Saved in:
Bibliographic Details
Published in:International journal of molecular sciences 2017-08, Vol.18 (9), p.1836
Main Authors: Lühder, Fred, Reichardt, Holger M
Format: Article
Language:English
Subjects:
Adrenal glands
Animal models
Animals
Arthritis
Asthma
Binding sites
Cancer
Cancer therapies
Cell culture
Clinical trials
Computational fluid dynamics
Drug delivery
Drug Delivery Systems
Drugs
Gene expression
Glucocorticoids
Glucocorticoids - administration & dosage
Glucocorticoids - pharmacology
Glucocorticoids - therapeutic use
Humans
Inflammation
Liposomes
Medical research
Micelles
Multiple sclerosis
Nanomedicine
Nanoparticles
neuroinflammation
Pharmacokinetics
Polymers
Review
rheumatoid arthristis
Rheumatoid arthritis
Scaffolds
Translational Medical Research
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Glucocorticoids (GC) are one of the most popular and versatile classes of drugs available to treat chronic inflammation and cancer, but side effects and resistance constrain their use. To overcome these hurdles, which are often related to the uniform tissue distribution of free GC and their short half-life in biological fluids, new delivery vehicles have been developed including PEGylated liposomes, polymeric micelles, polymer-drug conjugates, inorganic scaffolds, and hybrid nanoparticles. While each of these nanoformulations has individual drawbacks, they are often superior to free GC in many aspects including therapeutic efficacy when tested in cell culture or animal models. Successful application of nanomedicines has been demonstrated in various models of neuroinflammatory diseases, cancer, rheumatoid arthritis, and several other disorders. Moreover, investigations using human cells and first clinical trials raise the hope that the new delivery vehicles may have the potential to make GC therapies more tolerable, specific and efficient in the future.
ISSN:1422-0067
1661-6596
1422-0067
DOI:10.3390/ijms18091836